Skip to main content
 

Main menu

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Coming Next Month
    • Archives
    • Most-Read Papers of 2021
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2022 Call for Abstracts
    • 2021 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • Highlighted Articles
    • The Journal

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
American Association for Respiratory Care
  • Subscribe
  • My alerts
  • Log in
American Association for Respiratory Care

Advanced Search

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Coming Next Month
    • Archives
    • Most-Read Papers of 2021
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2022 Call for Abstracts
    • 2021 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • Highlighted Articles
    • The Journal
  • Twitter
  • Facebook
  • YouTube
Research ArticleOriginal Research

Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database

Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce and Sandra L Kane-Gill
Respiratory Care November 2021, 66 (11) 1739-1745; DOI: https://doi.org/10.4187/respcare.08809
Hyunwoo Kim
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin M Pfeiffer
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew P Gray
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Britney A Stottlemyer
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard D Boyce
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra L Kane-Gill
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    Forum of International Respiratory Societies. The Global Impact of Respiratory Disease, Second Edition. Sheffield, UK: Forum of International Respiratory Societies; 2017.
  2. 2.↵
    1. Kochanek KD,
    2. Murphy SL,
    3. Xu J,
    4. Arias E
    . Deaths: final data for 2017. Natl Vital Stat Rep 2019;68(9):1-77.
    OpenUrlPubMed
  3. 3.↵
    Global Asthma Network Steering Group, Global Asthma Network Study Group. Global Asthma Report 2014. Available at: http://globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf. Accessed March 25, 2021.
  4. 4.↵
    1. Nurmagambetov T,
    2. Kuwahara R,
    3. Garbe P
    . The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc 2018;15(3):348-356.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Ford ES,
    2. Murphy LB,
    3. Khavjou O,
    4. Giles WH,
    5. Holt JB,
    6. Croft JB
    . Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest 2015;147(1):31-45.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kim D,
    2. Chen Z,
    3. Zhou LF,
    4. Huang SX
    . Air pollutants and early origins of respiratory diseases. Chronic Dis Transl Med 2018;4(2):75-94.
    OpenUrl
  7. 7.↵
    1. Raj N,
    2. Fernandes S,
    3. Charyulu NR,
    4. Dubey A,
    5. G SR,
    6. Hebbar S
    . Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther Adv Drug Saf 2019;10:2042098619865413.
    OpenUrl
  8. 8.↵
    1. Caster O,
    2. Aoki Y,
    3. Gattepaille LM,
    4. Grundmark B
    . Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 2020;43(5):479-487.
    OpenUrlPubMed
  9. 9.↵
    1. Coleman JJ,
    2. Pontefract SK
    . Adverse drug reactions. Clin Med (Lond) 2016;16(5):481-485.
    OpenUrl
  10. 10.↵
    1. Mims JW
    . Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol 2015;5(Suppl 1):S2-S6.
    OpenUrl
  11. 11.↵
    1. Vestbo J
    . COPD: definition and phenotypes. Clin Chest Med 2014;35(1):1-6.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    AstraZeneca. Symbicort (budesonide and formoterol fumarate dihydrate). Available at: https://www.mysymbicort.com. Accessed May 12, 2021.
  13. 13.↵
    GlaxoSmithKline. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). Available at: https://www.mybreo.com. Accessed May 12, 2021.
  14. 14.↵
    GlaxoSmithKline. Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Available at: https://www.advair.com. Accessed May 12, 2021.
  15. 15.↵
    1. Banda JM,
    2. Evans L,
    3. Vanguri RS,
    4. Tatonetti NP,
    5. Ryan PB,
    6. Shah NH
    . A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data 2016;3:160026.
    OpenUrl
  16. 16.↵
    1. Donohue JF,
    2. Niewoehner D,
    3. Brooks J,
    4. O'Dell D,
    5. Church A
    . Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15(1):78.
    OpenUrlPubMed
  17. 17.↵
    1. Maltais F,
    2. Bjermer L,
    3. Kerwin EM,
    4. Jones PW,
    5. Watkins ML,
    6. Tombs L,
    7. et al
    . Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res 2019;20(1):238.
    OpenUrl
  18. 18.↵
    AstraZeneca. Daliresp (roflumilast). Available at: https://www.daliresp.com. Accessed May 12, 2021.
  19. 19.↵
    1. Rennard SI,
    2. Calverley PMA,
    3. Goehring UM,
    4. Bredenbröker D,
    5. Martinez FJ
    . Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011;12(1):18.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Cilli A,
    2. Bal H,
    3. Gunen H
    . Efficacy and safety profile of roflumilast in a real-world experience. J Thorac Dis 2019;11(4):1100-1105.
    OpenUrl
  21. 21.↵
    FDA Drug Safety Communication. FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). April 15, 2011. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes. Accessed March 1, 2021.
  22. 22.↵
    1. Welch HK,
    2. Kellum JA,
    3. Kane-Gill S
    . Drug-associated acute kidney injury identified in the United States Food and Drug Administration Adverse Event Reporting System database. Pharmacotherapy 2018;38(8):785-793.
    OpenUrl
  23. 23.
    1. Gray MP,
    2. Dziuba G,
    3. Quach K,
    4. Wong A,
    5. Smithburger PL,
    6. Seybert AL,
    7. Kane-Gill SL
    . Assessing adverse drug reactions from psychotropic medications reported to the U.S. Food and Drug Administration in older adults. Am J Geriatr Psychiatry 2019;27(2):181-185.
    OpenUrl
  24. 24.↵
    1. Patel NM,
    2. Stottlemyer BA,
    3. Gray MP,
    4. Boyce RD,
    5. Kane-Gill SL
    . A pharmacovigilance study of adverse drug reactions reported for cardiovascular disease medications approved between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Cardiovasc Drugs Ther. 2021 [Epub ahead of print].
  25. 25.↵
    1. Arora A,
    2. Jalali RK,
    3. Vohora D
    . Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag 2017;13:1195-1203.
    OpenUrl
PreviousNext
Back to top

In this issue

Respiratory Care: 66 (11)
Respiratory Care
Vol. 66, Issue 11
1 Nov 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author

 

Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Association for Respiratory Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
(Your Name) has sent you a message from American Association for Respiratory Care
(Your Name) thought you would like to see the American Association for Respiratory Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce, Sandra L Kane-Gill
Respiratory Care Nov 2021, 66 (11) 1739-1745; DOI: 10.4187/respcare.08809

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce, Sandra L Kane-Gill
Respiratory Care Nov 2021, 66 (11) 1739-1745; DOI: 10.4187/respcare.08809
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Limitations
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

Keywords

  • pharmacovigilance
  • post-marketing
  • chronic obstructive pulmonary disease
  • asthma
  • reporting odds ratio
  • adverse drug reaction

Info For

  • Subscribers
  • Institutions
  • Advertisers

About Us

  • About the Journal
  • Editorial Board
  • Reprints/Permissions

AARC

  • Membership
  • Meetings
  • Clinical Practice Guidelines

More

  • Contact Us
  • RSS
American Association for Respiratory Care

Print ISSN: 0020-1324        Online ISSN: 1943-3654

© Daedalus Enterprises, Inc.

Powered by HighWire